Rising tide of corporate venture financings: Data Byte

Private fund-raisings with participation by the corporate venture arms of biopharma companies have nearly doubled in number during the past five years, with the majority of the investments being made in series A and B rounds. 

Last year saw a jump in the number of corporate VC investments in seed, series A, B and C rounds compared with previous years as two trends collide to drive corporate venture arms earlier: the growing reliance of pharmas on their VCs to stay on top of rapid advances in technology and basic science, and increasing competition for late-stage investments by large private funds. ...